Article

Evaluation of the CombiChip Mycobacteria Drug-Resistance detection DNA chip for identifying mutations associated with resistance to isoniazid and rifampin in Mycobacterium tuberculosis.

Department of Clinical Pathology, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital, Suwon 442-723, South Korea.
Diagnostic Microbiology and Infectious Disease (Impact Factor: 2.26). 04/2006; 54(3):203-10. DOI: 10.1016/j.diagmicrobio.2005.09.014
Source: PubMed

ABSTRACT The CombiChip Mycobacteriatrade mark Drug-Resistance Detection DNA chip, recently developed by GeneIn (Pusan, South Korea), is an oligonucleotide microchip coupled with polymerase chain reaction for the detection of mutations associated with resistance to isoniazid (INH) and rifampin (RIF). This oligonucleotide chip was compared with DNA sequencing and phenotypic drug susceptibility testing with 69 INH- and/or RIF-resistant and 27 all tested drug-susceptible Mycobacterium tuberculosis isolates. Two selected codons (the katG codon 315 and inhA15) allowed identification of 84.1% of INH-resistant isolates and 100% of RIF resistance were detected by screening for 7 codons: rpoB511, rpoB513, rpoB516, rpoB522, rpoB526, rpoB531, and rpoB533. The overall specificity of this oligonucleotide chip for detecting INH and RIF resistance were 100 and 95.3%, respectively. This level of sensitivity and specificity is concordant with that from the determination of M. tuberculosis drug resistance by DNA sequencing. This oligonucleotide chip is a rapid and reliable genotypic method capable of detecting multiple mutations associated with INH and RIF resistance simultaneously in a single microchip slide.

0 Bookmarks
 · 
53 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A detailed review on the molecular evolution of the Mycobacterium tuberculosis complex that focuses on following topics: (i) A basic evolutionary scheme of mycobacteria, (ii) M. tuberculosis complex population molecular genetics, (iii) Co-evolution of M. tuberculosis with its hosts, (iv) M. tuberculosis through space and time, (v) Looking for robust evolutionary markers, (vi) Why repeated sequences were so useful at the beginning, (vii) Regions of differences (RDs) and SNPs in M. tuberculosis, (viii) Looking for congruence between polymorphic markers, (ix) Main lineages within the M. tuberculosis species, (x) When did the bovine-human switch of M. tuberculosis take place?, (xi) Comparative genomics and evolution of tubercle bacilli, (xii) Short-term evolutionary markers and database building, (xiii) Conclusion and Perspectives.
    06/2007: pages 53-91;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the diagnosis of mycobacteriosis and susceptibility testing are still primarily based on conventional methods (staining, culture, biochemical analysis, proportional method), a series of molecular assays are increasingly introduced and incorporated in the workflow of clinical mycobacteriology laboratories worldwide. These assays are rapid and offer high sensitivities and specificities. In the present review, we describe the molecular assays concerning the early detection of Mycobacteria in clinical specimens, the identification of mycobacterial species, the detection of drug resistance and the typing for epidemiological investigations.
    Journal of Microbiological Methods 01/2008; · 2.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this review is to describe the mechanisms of antimicrobial resistance and to present some genotypic drug resistance assays used to detect antimicrobial resistance. Genotypic drug resistance assays that are increasingly used in the clinical microbiology laboratory and their applications in the clinical settings will be further discussed.